Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Digital content for Arcturus Therapeutics

    Client Virtual Booth

    ARCTURUS THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Arcturus Therapeutics
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10628 Science Center Drive, Suite 250, San Diego, CA 92121, US
    Telephone
    Telephone
    (858) 900-2660
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://arcturusrx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/arcturus-therapeutics/
    Twitter
    Twitter
    https://twitter.com/ArcturusRx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    Meiji Seika to supply Japan with self-amplifying mRNA Covid-19 vaccine
    Meiji Seika to supply Japan with self-amplifying mRNA Covid-19 vaccine

    https://endpts.com/meiji-seika-pharma-to-supply-japan-with-self-amplifying-mrna-covid-19-vaccine-in-fall-winter-of-2024/

    ENDPTS
    22 Mar 2024
    Share Share
    Arcturus Announces Fourth Quarter and Fiscal Year 2023 Financial Progress
    Arcturus Announces Fourth Quarter and Fiscal Year 2023 Financial Progress

    https://www.businesswire.com/news/home/20240307376363/en

    BUSINESSWIRE
    07 Mar 2024
    Share Share
    Arcturus to Present at the Barclays 26th Annual Global Healthcare Conference
    Arcturus to Present at the Barclays 26th Annual Global Healthcare Conference

    https://www.businesswire.com/news/home/20240226871300/en

    BUSINESSWIRE
    26 Feb 2024
    Share Share
    Arcturus Receives Orphan Medicinal Product Designation from the EC for ARCT-032
    Arcturus Receives Orphan Medicinal Product Designation from the EC for ARCT-032

    https://www.businesswire.com/news/home/20240222266344/en

    BUSINESSWIRE
    22 Feb 2024
    Share Share
    Arcturus to Report Fourth Quarter and Full Year 2023 Financial Results
    Arcturus to Report Fourth Quarter and Full Year 2023 Financial Results

    https://www.businesswire.com/news/home/20240220483960/en

    BUSINESSWIRE
    20 Feb 2024
    Share Share
    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
    New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster

    https://www.businesswire.com/news/home/20240205318668/en

    BUSINESSWIRE
    05 Feb 2024
    Share Share
    PassPort Technologies Commences Collaborative Research with Arcturus
    PassPort Technologies Commences Collaborative Research with Arcturus

    https://www.prnewswire.com/news-releases/passport-technologies-commences-collaborative-research-with-arcturus-therapeutics-to-evaluate-transdermal-mrna-delivery-systems-302027399.html

    PR NEWSWIRE
    05 Jan 2024
    Share Share
    CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
    CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster

    https://www.businesswire.com/news/home/20231221709319/en

    BUSINESSWIRE
    21 Dec 2023
    Share Share
    Arcturus to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    Arcturus to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    https://www.businesswire.com/news/home/20231204612304/en

    BUSINESSWIRE
    04 Dec 2023
    Share Share
    Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib
    Exelixis and Arcus Announce Trial Collaboration to Evaluate Zanzalintinib

    https://www.businesswire.com/news/home/20231203437225/en

    BUSINESSWIRE
    04 Dec 2023
    Share Share
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    polpharma-m-2024-04-15

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search